SureTrader SPDR Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHAE)

Add RCHAE Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, sunspotter, onthegreen
Search This Board:
Last Post: 7/30/2015 10:39:44 AM - Followers: 157 - Board type: Free - Posts Today: 2

RCHA Patent for Treatment of Hodgkin’s Lymphoma
Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma, utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
RCHA Recent News
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014.  In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:


Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions. 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Daily View

Weekly View

3 Month Daily View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RCHAE News: Current Report Filing (8-k) 06/29/2015 04:29:11 PM
RCHAE News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 06/29/2015 11:07:55 AM
RCHAE News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 06/29/2015 09:56:25 AM
RCHAE News: Securities Registration: Employee Benefit Plan (s-8) 06/18/2015 05:16:57 PM
RCHAE News: Current Report Filing (8-k) 06/17/2015 05:08:23 PM
#7384  Sticky Note $RCHA recent news/filings mick 04/17/15 04:23:21 PM
#6618  Sticky Note "in the face of the massive gains we sunspotter 03/17/15 05:07:01 AM
#7972   It's been at a no bid for over Bankrupt1 07/30/15 10:39:44 AM
#7971   Stock gone to no bid, reverse split coming. stocksstockstocks 07/30/15 10:20:31 AM
#7970   Sorry pre clinical studies Revorising 07/29/15 10:00:00 PM
#7969   No way it runs to .07 like last Revorising 07/29/15 09:59:29 PM
#7968   Someone is accumulating cheap shares. Ask is dropping Axeman 07/29/15 09:31:25 PM
#7967   61 milly today... Lol Revorising 07/29/15 09:14:57 PM
#7966   People loading as if news is sure to Revorising 07/28/15 04:09:22 PM
#7965   What is going on here? NEWS IS NEEDED!!! ImHereToo 07/28/15 03:21:57 PM
#7964   They didn't even file bro Maybeismaybenot 07/28/15 02:33:04 PM
#7963   I can wait!!! Revorising 07/28/15 02:24:57 PM
#7962   Yes, they are! Stay tuned for 4th quarter. jonestint 07/28/15 02:24:29 PM
#7961   What is this??? People loading for something. Revorising 07/28/15 01:55:12 PM
#7960 mick 07/28/15 11:42:07 AM
#7959   Rchae status is now PooPoo. If you like stocksstockstocks 07/28/15 11:11:48 AM
#7958   People are accumulating, something strange is going on. Jclassy 07/28/15 12:16:17 AM
#7956   It just doesn't make sense that they would Revorising 07/26/15 01:43:03 PM
#7955   This company is fake all the news, everything stocksstockstocks 07/26/15 12:13:27 PM
#7954   So have we figured out if RCHA ever Revorising 07/24/15 09:41:21 PM
#7953   Ben, we need some POSITIVE NEWS, give us ImHereToo 07/23/15 12:51:41 PM
#7952   I have been holding long and strong, been ImHereToo 07/23/15 12:50:42 PM
#7951   There are many positives for this stock that ImHereToo 07/23/15 12:49:37 PM
#7950   I believe that there is a lot more ImHereToo 07/23/15 12:48:10 PM
#7949   I have heard this many times before BUT ??? bubbahlo 07/23/15 12:29:05 PM
#7948   Those people are the dumb money loading up. stocksstockstocks 07/23/15 11:28:42 AM
#7947   So why are people loading like no tomorrow??? Revorising 07/23/15 11:20:11 AM
#7946   looks like this is finished .. last one valleyview 07/23/15 07:36:29 AM
#7945   Stock is done. They wouldn't release updates and Bankrupt1 07/22/15 04:21:22 PM
#7944   Toxic Financing plain and simple. Axeman 07/22/15 03:11:35 PM
#7943   People are dumping all over!!!! Revorising 07/22/15 02:54:44 PM
#7942   Rcha gone to no bid, next comes the stocksstockstocks 07/22/15 02:06:17 PM
#7941   NO BID STOCK OUCH Thanks Ben. Axeman 07/22/15 01:33:10 PM
#7940   Looks like shareholders who bought are now selling stocksstockstocks 07/21/15 06:27:00 PM
#7939   People are still loading.... Unbeleivable.... Risk vs reward Revorising 07/20/15 08:12:55 PM
#7938   Sorry, no can do RCHA .. Admiral Lagrange 07/20/15 03:13:29 PM
#7937   opps !! Current OS 3,097,091,736. Admiral Lagrange 07/20/15 03:08:12 PM
#7936   current AS 37,503,000,000 Admiral Lagrange 07/20/15 02:58:54 PM
#7935   current OS 2,890,513,376 Admiral Lagrange 07/20/15 02:52:03 PM
#7934   Looks fine to me. L2 working fine too. Admiral Lagrange 07/20/15 01:12:57 PM
#7933   Ben Chang put two in the pink one Bankrupt1 07/17/15 01:44:48 PM
#7932   Rcha went from a QB to a stinky stocksstockstocks 07/17/15 10:47:12 AM
#7930   Comapny goes no bid in a week. The Bankrupt1 07/17/15 09:44:05 AM
#7929   somethings up ?? no quote ? no chart valleyview 07/17/15 07:56:29 AM
#7928   SEC Reporting - Delinquent. Ben needs to get Axeman 07/17/15 01:30:41 AM
#7927   People are still loading. Revorising 07/16/15 03:42:39 PM
#7926   So they are current? Revorising 07/16/15 02:39:10 PM
#7925   Profile Updated on PENNYMACHINE 07/16/15 02:37:23 PM
#7924   Ben Chang more like been unemployed. This company Bankrupt1 07/16/15 01:15:19 PM
#7923   Yup someone knows something, really. All they know m_m007 07/16/15 12:49:10 PM
#7922   Forget 10 it's .0001! Well so much for predictions. stocksstockstocks 07/16/15 11:03:50 AM